Harrow, Inc. Production Related Impairments or Charges
Harrow, Inc. (HROW) reported Production Related Impairments or Charges of $150.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ProductionRelatedImpairmentsOrCharges · last filed 2023-03-23
- Harrow, Inc. production related impairments or charges for fiscal 2021 was $150.00K, a 42.86% increase from fiscal 2020.
- Harrow, Inc. production related impairments or charges for fiscal 2020 was $105.00K.
| Period end | Production Related Impairments or Charges 12 month |
|---|---|
| 2021-12-31 | $150.00K 10-K · filed 2023-03-23 |
| 2020-12-31 | $105.00K 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |